Previous close | 3.2700 |
Open | 3.4050 |
Bid | 3.3950 x 0 |
Ask | 3.6400 x 0 |
Day's range | 3.4050 - 3.4050 |
52-week range | 0.9520 - 4.5000 |
Volume | |
Avg. volume | 6 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
Strong Utilization Trends and Operational Highlights Drive Growth